NCT03791593View on ClinicalTrials.gov

EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

July 20, 2022

Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

Evolocumab

Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.

Trial Locations (3)

41013

Hospital Universitario Virgen del Rocío, Seville

46010

Hospital Clínico de Valencia, Valencia

08916

Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors
lead

Fundació Institut Germans Trias i Pujol

OTHER

NCT03791593 - EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot | Biotech Hunter | Biotech Hunter